Search Results
Your search for ,aGO matches 1412 pages
Showing 551 - 600Small Study Investigates Rise of Glottic Carcinoma in Young Adults and HPV Infection
An increase in the diagnosis of glottic carcinoma in young adults may be due in part to infection with strains of human papillomavirus (HPV). Investigators from Massachusetts General Hospital (MGH) described finding HPV infection in all tested samples of glottic carcinoma from 10 patients diagnosed ...
Advancing the Science and Art of Integrative Oncology
In 2019, we will mark the 20th year of the establishment of the Integrative Medicine Service at Memorial Sloan Kettering Cancer Center (MSK), which helped lay the foundation for the emerging field of integrative oncology. Over the past 2 decades, academic cancer institutions, including The...
Living My Best Life
Five years ago, I was living my dream life. I was under contract as a commentator on Fox News, which necessitated commuting weekly from my home in Los Angeles to New York, and was building a new home in Palm Springs with my partner, Matt Lashey. Not only was my career and personal life going well,...
Obesity-Related Cancers Rising in Young Adults in the United States
A new study has found rates are increasing for 6 of 12 cancers related to obesity in younger adults in the United States, with steeper increases in progressively younger ages and successively younger generations. The study, published by Sung et al in The Lancet Public Health, also looked at rates...
Changing Perceptions on Surgical Intervention for Geriatric Patients With Cancer: Role of the SIOG Surgical Task Force
Surgery is an integral part of treatment of elderly patients with solid malignancies. The times we are living in will be remembered by health-care providers for the significant “contradictions” in the medical and surgical care of elderly patients with cancer. On the one hand, it has been...
Challenge Moving Forward in Breast Cancer Treatment: To Show That New Approaches Change Outcomes
ADVANCES IN treating breast cancer over the past 20 years have brought us to the point where treatment can be confidently de-escalated for some patients, and immunotherapy and precision decision-making may change the way breast cancer is treated for others, William Gradishar MD, FASCO, told the...
Primary Prophylaxis With a Direct Oral Anticoagulation Agent Reduces Venous Thromboembolism Rate in Ambulatory Patients With Cancer
LATE-BREAKING results from the large, randomized, placebo-controlled CASSINI trial showed that primary prophylaxis with the direct oral anticoagulation agent rivaroxaban reduced the incidence of venous thromboembolism (VTE) as well as VTE-related deaths in high-risk patients with cancer who were...
Role of Adjuvant Capecitabine in Triple-Negative Breast Cancer
ADJUVANT CAPECITABINE added to standard neoadjuvant chemotherapy failed to significantly improve disease-free or overall survival in patients with early triple-negative breast cancer in the large phase III CIBOMA/2004-01_GEICAM/2003-11 (CIBOMA/GEICAM) trial.1 However, extended treatment with...
Expert Point of View: Virginia G. Kaklamani, MD; Monica Morrow, MD; and John Cole, MD
AT THE SAN ANTONIO Breast Cancer Symposium, several breast cancer experts interviewed by The ASCO Post noted that the approved dose of tamoxifen was arbitrarily set, and the optimal dose is actually unknown. Studies of lower-dose tamoxifen, therefore, are welcomed. Virginia G. Kaklamani, MD,...
Newly Defined Subtypes of B-Cell Acute Lymphoblastic Leukemia
Investigators have identified multiple new subtypes of the most common childhood cancer, B-cell acute lymphoblastic leukemia (ALL)—research that has the potential to improve the diagnosis and treatment of high-risk patients. Researchers used integrated genomic analysis, including...
A Tribute to Arti Hurria, MD, FASCO, a Leader in Geriatric Oncology
The oncology community is deeply saddened by the untimely passing of Arti Hurria, MD, FASCO, a nationally regarded expert and advocate for elderly patients with cancer. Dr. Hurria died on November 7, 2018, in a traffic accident. At the time of her tragic death, Dr. Hurria was Director of the City...
Remnants of Cancer Remain, but Demons Are Now Gone
In the summer of 2002, I was a physically active 17-year-old boy on the cusp of adulthood. I was about to enter my senior year in high school, and like other teens my age, I was excited about college and the promise of the undreamed-of opportunities that lay ahead. At first, the lethargy I was...
I Welcome Being the Face of Multiple Myeloma
Thirteen years ago, at age 34, I was healthy and enjoying life. I went to the gym almost daily, and when I wasn’t at the gym, I was shooting hoops with my friends. During a gym workout while on a family vacation, I suddenly felt excruciating pain in my left shoulder and thought I must have strained ...
Illustrating Genius
FOUR AND A HALF YEARS AGO, author Neil Canavan attended a scientific conference to learn what he could about the then-emerging field of immunotherapy for cancer. After a presentation by Zelig Eshhar, PhD, principal investigator in the Department of Immunology at the Weizmann Institute of Science...
Global Oncology Education and Professional Development: ASCO International’s Impact
ASCO is such a misnomer: the American Society of Clinical Oncology is far more than simply “American.” Over the past several years, I (a Canadian-born breast surgical oncologist, with an Indian-born mother and a Tanzanian-born father) have traveled to Zimbabwe, Bhutan, and the Philippines with this ...
Should I Have Lied?
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Low-Dose CT Lung Screening: New Developments Support Increased Quality, More Data, Deep Learning
Two years ago, Rick Avila, MS, Chief Executive Officer (CEO) of Accumetra, LLC, was using rolls of Scotch tape as a research tool. The Scotch tape was a phantom, or reference object, and his company was working with computed tomography (CT) lung screening sites around the world to determine the...
RSNA 2018: Preliminary Results of Primary Cryoablation in Treating Low-Risk Breast Cancers
Cryoablation has shown early indications of effectiveness in treating women with low-risk breast cancers, according to research presented at the Annual Meeting of the Radiological Society of North America (RSNA) (Abstract SSM01-01). “If the positive preliminary findings are maintained as the ...
Role of Genomic Profiling in Younger Patients With Cancer
Although overall cancer survival rates continue to improve among all age groups in the United States—there are currently an estimated 15.5 million cancer survivors, and that number is expected to increase to 20.3 million by 20261—survival rates for adolescents and young adults with cancer (AYAs)...
Expert Point of View: Joaquin Mateo, MD, PhD
FORMAL DISCUSSANT Joaquin Mateo, MD, PhD, of the Prostate Cancer Translational Research Group, Vall d’Hebron Institute of Oncology, Barcelona, said that the TRITON2 findings were encouraging, although still preliminary. “We should interpret these results with caution, because this interim analysis ...
Local Consolidative Therapy Associated With Survival Benefit for Some With Oligometastatic NSCLC
FOR A SUBSET of patients with stage IV lung cancer, aggressive treatment may improve overall survival, according to data presented at the 2018 Annual Meeting of the American Society for Radiation Oncology (ASTRO).1 The results of the phase II study showed that with long-term follow-up, local...
Bonnie J. Addario Lung Cancer Foundation Honors Investigators, Clinicians, Caregivers
The Bonnie J. Addario Lung Cancer Foundation (ALCF) recognized outstanding contributors in research, treatment, and caregiving at its Simply the Best Dinner and Gala, which took place recently in San Francisco. The annual event is a celebration of survivors, hope, and determination that brings...
Neurologic Knowledge to Enhance Well-Being and Happiness
BOOKMARK Title: Your Happy Brain: Why and How to Hug ItAuthors: Philomena Lawrence, BA, BEd, and Gilbert Lawrence, MD, FRCRPublisher: CreateSpace Independent Publishing PlatformPublication date: June 2018Price: $16.00, paperback, 390 pages Some 2,400 years ago, the ancient Greeks were among the...
Denial’s Many Faces
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Palliative Care in the Pediatric Oncology Setting
Cancer is the leading cause of disease-related childhood death. To better serve the special needs of this highly vulnerable patient population, pediatric palliative care teams use a personalized, holistic, and interdisciplinary approach tailored to relieve the physical, psychosocial, and spiritual ...
FDA Approves Larotrectinib for Solid Tumors With NTRK Gene Fusions
On November 26, 2018, the U.S. Food and Drug Administration (FDA) granted accelerated approval to larotrectinib (Vitrakvi) for adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, whose...
Obligation to Evaluate Racial/Ethnic Features That May Affect Outcomes for Patients With Breast Cancer
"WE ABSOLUTELY have an obligation to evaluate all of the features describing our patients with cancer when we are trying to figure out why some patients do better than others,” Lisa A. Newman, MD, MPH, reminded the nearly 700 participants at the 2018 Lynn Sage Breast Cancer Symposium, hosted by...
Electronic ‘Datarrhea’ and Wellness
THE INTRODUCTION of the electronic health record (EHR) was supposed to lead us to a utopian world for health-care delivery in America. The Patient Protection and Affordable Care Act, signed into law on March 23, 2010, promoted its implementation by providing financial incentives.1 The Centers for...
UPMC Opens New Radiotherapy Center in Italy
The University of Pittsburg Medical Center (UPMC) recently announced the opening of a new radiotherapy center in Villa Maria, Italy, which will become part of the UPMC Hillman Cancer Center network when it opens to patients later this year. The new center, named the UPMC Hillman Cancer Center at...
Steven A. Rosenberg, MD, PhD, Works to Unmask Cancer’s Achilles Heel
Steven A. Rosenberg, MD, PhD, knew from the start of his medical career that if treatments for cancer were to become curative, research in new therapies would have to move away from the mainstay one-size-fits-all approach of systemic chemotherapy to an innovative, personalized strategy that...
Expert Point of View: Sandro Pignata, MD
The study’s invited discussant, Sandro Pignata, MD, of the Istituto Nazionale Tumori di Napoli in Italy, called the data from AGO OVAR 2.21 “very strong.” He added: “We now have robust evidence from a trial of more than 600 patients, in which previous bevacizumab (Avastin) was allowed, that...
Study Identifies Suitable Partner for Bevacizumab in Recurrent Ovarian Cancer
For patients with recurrent ovarian cancer who receive platinum-based retreatment, the more suitable partner for bevacizumab (Avastin) may be carboplatin plus pegylated liposomal doxorubicin, rather than carboplatin and gemcitabine, according to the results of a phase III ENGOT/GCIG Intergroup...
Expert Point of View: Catherine C. Park, MD, FASTRO
Discussant of the 12-year report from the NRG/RTOG 9804 trial, Catherine C. Park, MD, FASTRO, Professor and Chair of the Department of Radiation Oncology at the University of California, San Francisco, underscored the high prevalence of ductal carcinoma in situ, which comprises approximately 20%...
Expert Point of View: Nadia Harbeck, MD, PhD, and Fatima Cardoso, MD
Serving as European Society for Medical Oncology (ESMO) expert at a press briefing, Nadia Harbeck, MD, PhD, Head of the Breast Center at the University of Munich, called the findings “practice-changing” in some parts of the world and “practice-reinforcing” in others. She said the 10-month...
ME STRONG Joins With ASCO’s Conquer Cancer Foundation to Support Research for Men’s Cancers and Neuroblastoma
ME STRONG, a nonprofit public charity in Deland, Florida, is one of the newest supporters of Conquer Cancer. Linda Ryan, ME STRONG co-founder and 16-year cancer survivor, understands the importance of research: it saved her life decades ago, and she’s relying on experimental treatment as she...
Samuel Waxman, MD, Receives China’s ‘Friendship Award’
The Samuel Waxman Cancer Research Foundation (SWCRF), an international nonprofit organization that funds cancer research, recently announced that its founder and Chief Executive Officer, Samuel Waxman, MD, has received China’s highest honor granted to a foreigner. The Vice-Premier of the People’s...
Thomas J. Dougherty, PhD, Father of Photodynamic Therapy, Dies at Age 85
Thomas J. Dougherty, PhD, the developer of modern photodynamic therapy and Chief Emeritus of Roswell Park’s Photodynamic Therapy Center, died October 2, 2018, in Buffalo, New York. “He was undoubtedly the major influence in bringing [photodynamic therapy] into the realm of cancer therapy,” said...
Living a Full Life After a Diagnosis of Cancer
BOOKMARK Title: Here We Grow: Mindfulness Through Cancer and BeyondAuthor: Paige DavisPublisher: She Writes PressDate: May 2018Price: $22.95, paperback, 154 pages Since the publication of Dr. Paul Kalanithi’s best-selling book, When Breath Becomes Air, about his diagnosis of cancer and untimely...
The Persephone Trial Reconsidered
Persephone is a 4,088-patient trial that Helena Margaret Earl, MBBS, PhD, reported at the 2018 ASCO Annual Meeting as establishing that 6 months of trastuzumab (Herceptin) is not inferior to 12 months in 4-year survival without invasive or local regional recurrence or distant metastases. Dr. Earl...
Health-Policy Forum Focuses on New Care-Delivery Paradigms
What was an MBA doing at the podium of a clinical oncology meeting? Ten years ago or so, that might have been surprising. But in an era of rapid change—in therapies, costs, payment models, and practice—it only makes sense. Amy Porter-Tacoronte, MBA, Health System Chief Administrative Officer at the ...
I’m Not Dying of Cancer: I’m Living With Cancer
I’m a psychiatrist, so I don’t say this lightly: receiving a diagnosis of stage IV gastric adenocarcinoma made me insane. I had remembered the horrible deaths due to abdominal cancer I had seen during my medical training and was terrified that would be my fate as well. I knew from looking at the...
Big Data and Breast Cancer: Moving the Field Forward Through Comprehensive Analysis
To gain further insight into, among other things, optimizing big data and the latest on hormonal breast cancer treatment, The ASCO Post recently spoke with pioneering oncologist Christopher C. Benz, MD, a breast cancer specialist and Director of the Cancer & Developmental Therapeutics Program, ...
Has the Promise of Precision Medicine Been Oversold?
Recently, the term “personalized medicine” in oncology care has been overtaken by the more contemporary concept of “precision medicine.” According to the National Research Council of the National Academies of Science, Engineering, and Medicine, the newer terminology shifts the focus to improving...
On the Frontier of Breast Cancer Research With Joyce A. O’Shaughnessy, MD
Nationally regarded breast cancer researcher and clinician Joyce A. O’Shaughnessy, MD, was born in upstate New York, just outside of Albany, where she attended grade school before her family moved to Beverly, Massachusetts, a suburban town 26 miles from Boston, where her family’s roots were....
Cabozantinib in Advanced Hepatocellular Cancer: Call for Revision of Practice Standards
As reported in The New England Journal of Medicine by Ghassan K. Abou-Alfa, MD, and colleagues, and reviewed in this issue of The ASCO Post, the phase III CELESTIAL trial has demonstrated that cabozantinib (Cabometyx) improved the median overall survival to 10.2 months in comparison to 8 months...
How the Nobel Prize Could Spur More Cancer Advances
Even before James P. Allison, PhD, made an appearance at the Fourth International Cancer Immunotherapy Conference: Translating Science Into Survival in New York City, the excitement among attendees was palpable. Earlier that day, October 1, 2018, Dr. Allison and Tasuku Honjo, MD, PhD, of Kyoto...
Regular Aspirin Use and Reduction in Risk for Hepatocellular Carcinoma
A pooled analysis of two large U.S. prospective cohort studies reported in JAMA Oncology by Simon et al indicates that regular use of aspirin is associated with a significant reduction in risk for hepatocellular carcinoma (HCC), with an apparent dose- and duration-dependent effect. Study Details...
Living a Purposeful Life Is My Revenge on Cancer
There is a lot of breast cancer in my family history. My mother was diagnosed with the disease at 44, and my paternal grandmother died of breast cancer when she was just 33, so I’ve always been diligent about performing breast self-exams— often weekly—to ensure that if I did get breast cancer, it...
Learning to Listen and Returning to the Art of Medicine
Bernard Lown, MD, was born in Lithuania, the son of a rabbi. He immigrated to the United States at the age of 14, where his scientific precocity bloomed. After attaining his medical degree from John Hopkins University School of Medicine, he pursued his passion of raising international awareness of...
On Aging and the Wellness Industry
Only a few centuries ago, the major source of moral and scientific authority in Western culture was religion, which requires trusting one of numerous supernatural deities. However, the presumption that medicine is based on evidence-based and peer-reviewed science is what gives it authority in...
